DDInter704 DDInter1400
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Everolimus {u} (Compound) upregulates {v} (Gene) STK10
STK10 {u} (Gene) is bound by {v} (Compound) Pazopanib
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pazopanib
Everolimus {u} (Compound) upregulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Everolimus {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Pazopanib
Everolimus {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Everolimus {u} (Compound) downregulates {v} (Gene) HACD3
HACD3 {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Everolimus {u} (Compound) causes {v} (Side Effect) Rhinorrhoea
Rhinorrhoea {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Everolimus (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Everolimus (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Pazopanib (Compound)
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound)
Everolimus (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Pazopanib (Compound)
Everolimus (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is upregulated by Pazopanib (Compound)
Everolimus (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Pazopanib (Compound)
Everolimus (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is downregulated by Pazopanib (Compound)
Everolimus (Compound) downregulates HACD3 (Gene) and HACD3 (Gene) is downregulated by Pazopanib (Compound)
Everolimus (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Pazopanib (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib